🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the UK / NCT06181240
Active, not recruiting Not applicable

Modification of Coronary Calcium With Laser Based Intravascular Lithotripsy for Coronary Artery Disease (FRACTURE)

NCT06181240 · tracked via the Priya Life Science UK tracker
Sponsor
Bolt Medical
Phase
Not applicable
Started
2024-01-19
Last updated
2026-07-14

Condition(s) studied

Coronary Artery DiseaseCoronary Artery Calcification

Investigational drug(s) / intervention(s)

Intravascular lithotripsy

Intravascular lithotripsy: Lithotripsy-enhanced percutaneous coronary intervention of de novo, calcified, stenotic coronary artery lesions prior to stenting.

Study summary

The FRACTURE Trial is a prospective, non-randomized, single-arm, multicenter, interventional study in US and international centers.

Eligibility

Sex
ALL
Min age
18 Years
Max age
Healthy volunteers
No
Key Inclusion Criteria: * Subject is ≥18 years of age; * Subjects with native coronary artery disease (including stable or unstable angina and silent ischemia) suitable for Percutaneous Coronary Intervention (PCI); * For patients with unstable ischemic heart disease, a local site-based biomarker (preferably troponin or hs-troponin) must be less than or equal to the upper limit of lab normal (ULN) within 12 hours prior to the study procedure; * For patients with stable ischemic heart disease, CK-MB will be drawn at the time of the study procedure from the side port of the sheath; results need not be analyzed prior to enrollment, but must be less than or equal to the upper limit of lab normal (ULN); * Single de novo target lesion stenosis of protected LMCA, or LAD, RCA, or LCX (or of their branches) with: * Stenosis of ≥70% and \<l00%; or * Stenosis ≥50% and \<70% (visually assessed) with evidence of ischemia via positive stress test, or fractional flow reserve value ≤0.80, or iFR \<0.90, or IVUS or OCT minimum lumen area ≤4.0 mm2; * Evidence of calcification at the target lesion site by * angiography, with fluoroscopic radiopacities noted without cardiac motion prior to contrast injection involving both sides of the arterial wall in at least one location and total length of calcium of at least 15 mm and extending partially into the target lesion, or * Intravascular Ultrasound (IVUS) or Optical Coherence Tomography (OCT), with presence of ≥270 degrees of calcium on at least 1 cross section; * Ability to pass a 0.014" guidewire across the lesion. Key Exclusion Criteria: * Subject experienced an acute MI (STEMI or non-STEMI) within 30 days prior to index procedure; * New York Heart Association (NYHA) class III or IV heart failure at time of index procedure; * Prospective need for hemodynamic support, i.e., IABP or Impella; * Chronic kidney disease with serum creatinine \>2.5 mg/dL, eGFR \<30 mL/min/1.73m2, or on chronic dialysis; * Unprotected left main diameter stenosis \>50%; * Target vessel is excessively tortuous defined as the presence of two or more bends \>90º or three or more bends \>75º; * Target lesion is an ostial location (LAD, LCX, or RCA, within 5 mm of ostium) or an unprotected left main lesion; * Chronic Total Occlusion; * Target lesion is located in a native vessel that can only be reached by going through a saphenous vein or arterial bypass graft;

Primary outcome measure(s)

Trial sites (46)

FacilityCityRegionStatus
Scripps Health La Jolla California
Cedars-Sinai Heart Institute Los Angeles California
Riverside Community Hospital Riverside California
Southern California Permanente Medical Gp. / Kaiser Permanente San Diego California
Los Robles Hospital & Medical Center Thousand Oaks California
Medical Center of the Rockies Loveland Colorado
Nova Clinical Research Centers/Manatee Memorial Hospital Bradenton Florida
The Cardiac & Vascular Institute Gainesville Florida
HCA FL Memorial Hospital Jacksonville Florida
HCA Florida Largo Hospital Largo Florida
Northeast Georgia Medical Center Gainesville Georgia
Wellstar Research Institute Hiram Georgia
Brigham and Women's Hospital Boston Massachusetts
Massachusetts General Hospital Boston Massachusetts
Trinity Health Michigan Heart Ypsilanti Michigan
Metropolitan Heart and Vascular Institute Coon Rapids Minnesota
North Mississippi Medical Center Tupelo Mississippi
Saint Luke's Hospital of Kansas City Kansas City Missouri
The Valley Hospital Paramus New Jersey
New York-Presbyterian/Brooklyn Methodist Hospital Brooklyn New York
The Icahn School of Medicine at Mt. Sinai New York New York
Nyph/Cuimc New York New York
Montefiore Medical Center The Bronx New York
NC Heart and Vascular Research Raleigh North Carolina
Providence Heart Institute Portland Oregon
Wellspan York Hospital York Pennsylvania
Tristar Centennial Medical Center Nashville Tennessee
Austin Heart Research Austin Texas
Methodist Healthcare Methodist Research Institute San Antonio Texas
Intermountain Health Murray Utah
Chippenham Johnson Willis Hospital Richmond Virginia
Onze-Lieve-Vrouwziekenhuis, afgekort OLV ziekenhuis Aalst Belgium
Aarhus University Hospital Aarhus Denmark
Segeberger Kliniken GmbH, Bad Segeberg Germany
Cellitinnen Krankenhaus St. Vinzenz Cologne Germany
SJG St. Paulus GmbH, St.-Johannes-Hospital Dortmund Dortmund Germany
Klaipeda University Hospital Klaipėda Lithuania
Vilnius University Hospital Santaros Klinikos Vilnius Lithuania
Amsterdam University Medical Center Amsterdam Netherlands
Erasmus Medical Center Rotterdam Netherlands

+ 6 more sites — see the full list on the official registry below.

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06181240 on ClinicalTrials.gov ↗ ← All trials in the UK